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Antisynthetase syndrome is a rare chronic autoimmune inflammatory myopathy with
fever, interstitial lung disease, Raynaud’s phenomenon and polyarthritis. The exact
underlying cause of antisynthetase syndrome is not yet known. Diagnosis is made
with presence of Jo-1 (Histydyl t RNA synthase) antigen in a patient with underlying
interstitial lung disease, myositis, arthritis, Raynaud’s phenomenon and mechanic’s
hand. Some of the other antisynthetase anti bodies are PL-7 (antigen – threonyl-tRNA
synthase), PL-12 (antigen - Alanyl-tRNA synthetase), OJ (antigen – Isoleucyl-tRNA
synthetase), EJ (antigen - Glycyl-tRNA synthetase), KS (Antigen – Asparaginyl-
tRNA synthetase, WA (Antigen- Autoantibody to a 48 kDa transfer RNA related
protein), YRS (antigen - Tyrosyl-tRNA synthetase) however the prevalence is found
to be highest with anti Jo-1 antibody (25-30%). In a patient with nonspeciﬁc
interstitial pneumonitis, Raynaud’s phenomenon and arthralgia antisynthetase
syndrome can be best diagnosed with anti ZO ab, though prevalence of the disease is
not yet known and in a patient with usual interstitial pneumonitis and fever diagnosis
of anti synthetase syndrome can be made with anti KS antibodies. Symptomatic
treatment is preferred, which may include immunosuppressive therapy and
corticosteroids especially in a patient with muscle and lung involvement.
I. Introduction
Anti synthetase syndrome is a very rare entity and only a few case have been studied. It effects mostly females and
is assumed to have a genetic predisposition, after certain viral infection or after certain drug use. Some studies also
suggest that various types of cancers are also associated with antisynthetase syndrome. The most common
symptoms includes fever, loss of appetite, loss of weight, myositis, polyarthritis, interstitial lung disease, mechanic’s
hands and Raynaud’s phenomenon. The prognosis of the disease is mostly depends on the extent of lung
parenchymal involvement.
We hereby report a case of 33 years old lady presented to the emergency room with complains of fever, worsening
of shortness of breath, polyarthritis for 6 weeks duration associated with weight loss and was previously diagnosed
to have Raynaud’s phenomenon. Her serology revealed antibodies against Jo-1 antigen and was started on
corticosteroids and immunosuppressive therapy. However by the time anti Jo-1 ab was found to be positive, the
extent of pulmonary involvement was massive and even on mechanical ventilator and other supports patient
deteriorated and succumb to death.
II. Case report
A 33 old normotensive, non-diabetic lady presented to the emergency room with complains of fever, worsening of
shortness of breath, polyarthritis for 6 weeks duration associated with weight loss. She also complained of numbness
and color changes of digits on cold exposure. Her presentation was gradual and progressive in onset following an
episode of high fever for which she was hospitalized and managed on empiric antibiotic therapy 6 weeks back.
Initially she had responded well to the anti biotic therapy but had relapsed. She was previously diagnosed to have
Raynaud’s phenomenon and was on conservative management. She had no complains or any previous history oral
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ulcers, malar rash, photosensitivity hair loss redness of eyes, serositis, seizures, weakness (Proximal/distal), skin
tightening, chest pain, palpitation, hemoptysis, COPD, bronchial asthma, pulmonary embolism or any
thromboembolic events (CVA, MI, amaurosis fugax, limb ischemia or recurrent pregnancy loss) in other system in
the past. Her general examination revealed a dyspnoeic, febrile (102.3 F) patient with tachycardia (124b/min -
regular), B.P (140/90mmHg), tachypnea (22/min). Chest examination revealed bilateral extensive rales and a few
rhonchi. Other systemic examination was unremarkable. Initial blood investigations at the time of admissions were
Hb - 14.1gm/dl, TLC – 32,100 cells/mm3 with 90% PMNs, platelet count – 3,47,000 cells/mm3, Na – 139 mmol/L;
K – 3.9 mmol/L; Creatinine – 0.9 mg/dl; Urea – 21 mg/dl, serum protein – 5.46g/dl; albumin – 2.6g/dl; globulin –
2.96g/dl; bilirubin – 0.76mg/dl; AST – 122 IU/L; ALT – 208 IU/L; Alkaline Phosphatase – 117 IU/L. Arterial
Blood Gases revealed pH – 7.48; pO2 – 44; pCO2 – 30; HCO3 – 18. ECG was fine.
CXR (Fig: 1) revealed diffuse bilateral haziness
III.
IV.
HRCT (Fig2, 3, 4) revealed extensive ground glassing opacification in bilateral lungs with irregular patchy
infiltration in both lung bases
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Patient was started on intravenous antibiotics and non-invasive mechanical ventilation, which was later, switched to
invasive ventilation, as high pressures were required to generate the required tidal volume. Differential diagnoses
entertained were BOOP, Sarcoidosis and Hamman Rich Syndrome and was started on pulse Methyl Prednisolone
therapy. Bronchoscopy revealed a clean endobronchial tree; bronchoalveolar lavage (BAL) obtained from RML and
RLL was pauci-cellular with bronchial epithelial cells, macrophages and few inflammatory cells (N - 80%; L - 20%).
Biopsy was not taken in view of high ventilatory requirements and poor general condition of the patient. Blood
serology revealed Rheumatoid Factor and Antibodies against Jo-1 antigen positive. ANA, ANCA and Quantiferon
Gold were negative; IgA, IgG and IgM levels were normal. Antibodies against HIV, HBV and HCV were negative.
In view of Anti Jo-1 antibodies positive another differential diagnosis of antisynthetase antibody syndrome was
made. She was continued with pulse Methyl Prednisolone therapy to which she responded favorably and by 10 days
of therapy her blood counts had improved substantially and had good hemodynamics. She was extubated and
maintained good oxygenation on non-invasive ventilation. However after this she developed acute onset
quadriparesis with proximal muscles more affected and had sluggish reflexes, respiratory muscle weakness with a
CPK level of 509 and normal MB fraction. In view of respiratory fatigue she was re intubated and started on IV
Cyclophosphamide but her general condition gradually deteriorated and she finally expired.
III. Discussion
The patient was suspected to have antisynthetase syndrome on the basis of Raynaud’s phenomenon, arthralgia and
pulmonary infiltrates. She was found to have antibodies to Jo-1 (histidyl-transfer RNA (tRNA) synthetase) using
enzyme-linked immunoabsorbant assay (ELISA). Bronchoscopy with lavage and trans bronchial lung biopsy (at
other center) showed no evidence of infectious or granulomatous disease probably because tissue samples were too
small for precise histological diagnosis and therefore bronchoscopy and bronchoalveolar lavage was repeated again
at our center but biopsy was avoided as the patient was on pressure control ventilation requiring high positive end
expiratory pressure (PEEP). The CD4:CD8 ratio from bronchoalveolar lavage was not available and muscle biopsy
was planned the next day, however the patient expired before it could be executed.
The antisynthetase syndrome belongs to the group of idiopathic inflammatory muscle diseases. The key clinical
features of this syndrome are acute Polymyositis/dermatomyositis (PM/DM) at its onset, fever and symmetrical non-
erosive arthritis, mechanic’s hands, Raynaud’s phenomenon and interstitial lung disease [1, 5]. The hallmark of the
disorder is the presence of specific autoantibodies that recognize aminoacyl-tRNA synthetases but the most common
lab investigations done on routine basis, is anti-Jo-1, which closely correlates with fibrosing alveolitis [6]. Among
the remaining antisynthetase, anti-PL12 is found in 2–5% of patients with PM/DM and can be associated with
isolated pulmonary fibrosis [5]. A small percentage (2–11%) of patients with dermatomyositis [5] do not have
muscle involvement (amyopathic dermatomyositis or dermatomyositis sine myositis) but about 60% of these
patients have anti-PL12 antibodies and 20% have anti-Jo-1 antibodies as in our patient [5]. In PM/DM, interstitial
lung disease is the major clinical problem in patients with the Antisynthetase syndrome [7] and shares similarities
with idiopathic pulmonary fibrosis or scleroderma-related pulmonary disease [7] and therefore determines the
overall prognosis, having a mortality of over 40%. The prevalence of the disease appears to be greater in patients
with positive anti-Jo-1 antibodies [1, 6, 7]. Interstitial lung disease may clinically present with persistent cough,
chest pain, diminished exercise tolerance, dyspnea at rest, or even acute respiratory failure [7]. Moreover, dyspnea
may be due to respiratory muscle weakness, drug-induced pneumonitis especially by methotrexate, pneumonia and
less commonly due to fibrosis. Lung involvement with an acute aggressive alveolitis overshadowing the myopathy
is rare [7]. Digital clubbing can occur, but less frequently than in idiopathic pulmonary fibrosis. Idiopathic
pulmonary fibrosis may be the first and only manifestation, which can rapidly evolve into diffuse alveolar damage
[1,5] and shows no response to steroid treatment and eventually patient succumbs to death. Therefore it is important
to identify patients with amyopathic DM and non-specific interstitial pneumonitis (NSIP) early in the disease course
and institute therapy prior to development of diffuse alveolar damage.
Pulmonary function test showing a characteristic restrictive impairment, chest radiographs revealing bilateral and
predominantly basilar interstitial infiltrates and HRCT revealing ground glass, linear infiltrates appearing as
irregular opacities, airspace consolidation, parenchymal micro nodules, or honeycombing pattern are the features of
this disease. The bronchoalveolar lavage (BAL) in an early stage of the disease may show lymphocytic alveolitis
with high CD8+ T cells counts, which denotes good response to steroids. The presence of eosinophils and
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neutrophils are found less commonly and indicates progression to fibrosis. Lung biopsy may reveal NSIP; diffuse
alveolar damage, usual interstitial pneumonia (UIP) and bronchiolitis obliterans organizing pneumonia (BOOP) [7].
Treatment with steroids usually with prednisone in the range of 60 mg/day seems to be effective for controlling the
extra-pulmonary manifestations of the syndrome. Patients with NSIP or BOOP have a more favorable prognosis
than patients with UIP or diffuse alveolar damage [7], because these are usually steroid-resistant and may require
additional immunosuppressive treatment.
Interstitial lung disease shows poor respond to steroids and the optimal treatment for these patients has yet to be
established.
IV. Conclusion
Antisynthetase syndrome should be considered in patients with interstitial lung disease even without evidence of
myositis. Early diagnosis and early institution of immunosuppressive therapy may change clinical course of the
syndrome though most of them have a steep downhill course. The role of Intravenous immunoglobulin and steroids
which usually improves muscle strength and has not been elucidated in patients with antisynthetase syndrome and
needs further study
REFERENCES
1. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the
classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful
homogenous patients groups. Medicine 70:360–374
2. Hochberg MC, Feldman D, Stevens MB (1986) Adult onset PM/DM: an analysis of clinical and laboratory
features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 15:168–178
3. el-Azhary RA, Pakzad SY (2002) Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad
Dermatol 46:560–565
4. Caproni M, Cardinali C, Parodi A et al (2002) Amyopathic dermatomyositis: a review by the Italian
Group of Immunodermatology. Arch Dermatol 138:23–27
5. Friedman AW, Targoff IN, Arnett FC (1996) Interstitial lung disease with autoantibodies against
aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 26:459–
467
6. Phillips TJ, Leigh IM, Wright J (1987) Dermatomyositis and pulmonary fibrosis associated with anti-Jo1
antibody. J Am Acad Dermatol 17(2 Aug Pt 2): 381–382.
7. Interstitial lung disease in a patient with Antisynthetase syndrome and no myositis: Sotiris C. Plastiras .
Fotini C. Soliotis. Panayiotis Vlachoyiannopoulos . George E. Tzelepis Clin Rheumatology (2007) 26:
108–111
Open Access Journal
International Journal of Medical Research and Pharmaceutical Sciences
Volume 4 (Issue 2) : February 2017 ISSN: 2394-9414
DOI- 10.5281/zenodo.322343 Impact Factor- 3.109
© International Journal of Medical Research and Pharmaceutical Sciences http://www.ijmprsjournal.com
45
Author Bibliography
Dr. Shahid Mahdi
DNB (Respiratory medicine), FRCCM (SINGAPORE), MNCCP, MISCCM.
Associate Director and Head
Cardiac Intensive Care
BLK Super specialty hospital,
New Delhi
mahdishahid@gmail.com
Dr. Darpanarayan Hazra
MBBS
Junior resident
Cardiac Intensive Care
BLK Super specialty hospital,
New Delhi
drdarpahazra@gmail.com
Dr. Zainab Mahdi
MBBS, DNB (student)
Emergency medicine
Fortis Hospital,
Mohali
itszainab@gmail.com
